New Partnership Embarks on European SonoDrugs Project
Philips Leads European SonoDrugs Project to Develop Image-Guided Localized Drug Delivery Technologies
€15.9 million project improve drugs’ efficiency and minimize side effects
Royal Philips Electronics is leading a major new European project to develop drug delivery technologies that could change the way treatment for cancer and cardiovascular disease is delivered.
By delivering drugs directly to disease sites via the patient’s bloodstream that are then activated by focused ultrasound pulses, the SonoDrugs project aims to maximize the therapeutic efficiency and minimize the side effects of drug treatments for cancer and cardiovascular disease. The hope is that this level of control will also provide a means of tailoring the therapy to individual patients.
The SonoDrugs project is a partnership between 15 European Union-based industrial partners, university medical centers, and academic institutions. It will run for four years and has a budget of €15.9 million, €10.9 million of which is funded under the EU’s 7th Framework program. http://cordis.europa.eu/fp7/home_en.html <http://cordis.europa.eu/fp7/home_en.html>
The SonoDrugs project has a two-pronged approach: the first is based on magnetic resonance imaging (MRI) guidance and the second on ultrasound guidance. The MRI-guided drug delivery will focus on cancer treatments.
Members of the SonoDrugs consortium are:
* The industrial partners Philips (The Netherlands, Germany and Finland), Nanobiotix (France) and Lipoid (Germany).
* The university medical centers Erasmus Medical Center (The Netherlands) and Universitäts Klinikum Münster (Germany).
* The academic institutions University of Cyprus (Cyprus), University of Gent (Belgium), University of Helsinki (Finland), University of London (United Kingdom), University of Tours (France), University Victor Segalen Bordeaux (France), University of Technology Eindhoven (The Netherlands) and the University of Udine (Italy).
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
